For The Better

An analyst chopped his price target on the AI equipment specialist.

Credit card program doubled cardholders as cash reserves grew to $28.4 million.

Revenue fell 36% as company pivots to enterprise accounts amid macroeconomic uncertainty.

Segment income climbed to $4.3 million amid insurance and asset management growth.

Adjusted EBITDA rises as portfolio reshaping offsets volume declines.

Subscription revenue jumped to $3.2 million amid shift to data-driven services.

Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.

Revenue grew to $3.1 million despite academic funding headwinds.

Revenue doubled as Vivistim unit sales and active territories expanded.

Florida Canyon mine hits record production rates while advancing DeLamar permitting.

GLP-1 drugs aren’t just for weight loss.

Backlog doubled to $2 billion as AI infrastructure demand surges.

Cespira revenue surged 125% while net losses narrowed significantly.

Military contracts boost revenue; full-year guidance raised to $15M.

Revenue plunged as ESS pivots to sodium-ion Bridge platform.

Product revenue surged 78% YoY as launches drive margin expansion and extend cash runway.

Strategy is no longer buying Bitcoin. That should concern investors.

Docusign is still growing, profitable, and surprisingly cheap–but its moat may be vulnerable. See why our analysts scored the stock 6.7 out of 10 and both prefer Adobe.

VigilAigent acquisition adds $3.5M ARR as company targets 2027 profitability.

Revenue grew to $2 million as spectrum monetization opportunities expand.